Zacks Research Upgrades Lyell Immunopharma (NASDAQ:LYEL) to Hold

Lyell Immunopharma (NASDAQ:LYEL) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research analysts have also issued reports on LYEL. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Lyell Immunopharma in a research report on Thursday, May 7th. Citizens Jmp began coverage on Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, Robert W. Baird set a $49.00 price objective on Lyell Immunopharma and gave the company an “outperform” rating in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.00.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $16.13 on Monday. Lyell Immunopharma has a 1 year low of $7.65 and a 1 year high of $45.00. The firm has a market capitalization of $376.31 million, a price-to-earnings ratio of -1.17 and a beta of -0.05. The business’s 50 day moving average price is $21.40 and its 200-day moving average price is $23.58.

Lyell Immunopharma (NASDAQ:LYEL) last announced its earnings results on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.10). Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%.The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. On average, sell-side analysts expect that Lyell Immunopharma will post -8.37 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. BBR Partners LLC purchased a new position in shares of Lyell Immunopharma during the 4th quarter worth $210,000. ExodusPoint Capital Management LP purchased a new position in shares of Lyell Immunopharma during the 4th quarter worth $262,000. Marshall Wace LLP purchased a new position in shares of Lyell Immunopharma during the 2nd quarter worth $94,000. Jane Street Group LLC purchased a new position in shares of Lyell Immunopharma during the 4th quarter worth $382,000. Finally, Barclays PLC raised its holdings in shares of Lyell Immunopharma by 1,239.5% during the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock worth $491,000 after acquiring an additional 14,775 shares during the period. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.